InvestorsHub Logo
Followers 6
Posts 4111
Boards Moderated 0
Alias Born 12/14/2009

Re: gold007_2000 post# 93957

Monday, 03/04/2019 2:59:43 PM

Monday, March 04, 2019 2:59:43 PM

Post# of 108192
Biotech deal-making is hot, but only for companies with promising data and platforms that are in demand. Then on the other end, you have companies that are valued at next to nothing for good reason. Amgen got a glimpse of the early data from NEO and decided further investment was not worth it and they would rather write off $65 million already invested since they think the probability for success is lower now that they have assessed the initial data than when they initially invested on optimistic expectations without data in hand.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News